Immunovant CFO exercises options and sells 10,000 shares
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at a price of $15.90 per share and then sold 10,000 shares in open-market transactions at a weighted average price of $38.46 per share. After these transactions, he directly holds 247,596 Common Shares. The filing notes that the sale was executed in multiple trades between $38.00 and $38.90 per share.
Insider Trade Summary
Exercise and Sale: 10,000 shares ($226K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Girao Tiago
Role
Chief Financial Officer
Sold
10,000 shs ($385K)
Approx. gross sale proceeds
$385K
Approx. exercise cost
$159K
Approx. pre-tax spread
$226K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $15.90 | $159K |
| Sale | Common Stock | 10,000 | $38.46 | $385K |
Holdings After Transaction:
Stock Option (right to buy) — 283,505 contracts (Direct);
Common Stock — 247,596 shares (Direct)
Footnotes (2)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2. Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.
Key Figures
Shares sold: 10,000 shares
Weighted average sale price: $38.46 per share
Sale price range: $38.00–$38.90 per share
+5 more
8 metrics
Shares sold
10,000 shares
Common Stock sold in open-market transactions
Weighted average sale price
$38.46 per share
Common Stock sale on 2026-06-26
Sale price range
$38.00–$38.90 per share
Multiple transactions, weighted average disclosed
Options exercised
10,000 shares
Stock Option (right to buy) converted into Common Stock
Exercise price
$15.90 per share
Conversion or exercise price for stock options
Shares held after transaction
247,596 shares
Direct Common Stock ownership following sale
Option grant date
May 1, 2025
Grant date for stock option award described in footnote
Initial vesting date
April 21, 2026
25% of option award vests on this date
Key Terms
weighted average price, stock options, grant date, vest, +1 more
5 terms
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"Award of stock options to purchase Common Shares with a grant date of May 1, 2025."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
grant date financial
"Award of stock options to purchase Common Shares with a grant date of May 1, 2025."
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest financial
"The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Stock Option (right to buy) financial
"Stock Option (right to buy) reported as a derivative security with underlying Common Stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immunovant (IMVT) report for Tiago Girao?
Immunovant reported that CFO Tiago Girao exercised stock options for 10,000 Common Shares and sold 10,000 shares in the open market. The exercise price was $15.90 per share and the weighted average sale price was $38.46 per share.
What stock options did the Immunovant (IMVT) CFO exercise in this filing?
The Form 4 shows Tiago Girao exercised stock options covering 10,000 shares of Common Stock at a conversion or exercise price of $15.90 per share. This exercise is paired with a derivative entry for a Stock Option (right to buy) linked to the same 10,000 underlying shares.
What vesting terms are disclosed for the Immunovant (IMVT) CFO’s stock options?
A footnote describes an award of stock options with a grant date of May 1, 2025. Twenty-five percent of the underlying shares vest on April 21, 2026, with the remaining options vesting in 12 substantially equal quarterly installments over three years, subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
